Evommune: Validating External Data and Pipeline Lead Position Support Buy Rating and Upside Potential

William Blair analyst Matt Phipps has reiterated their bullish stance on EVMN stock, giving a Buy rating on February 19.

Matt Phipps has given his Buy rating due to a combination of factors tied to both Evommune’s pipeline position and validating external data. He notes that new Phase I results from Septerna’s SEP-631, another oral MRGPRX2 inhibitor, show a dose-dependent effect in an icatibant skin challenge that closely mirrors the pharmacodynamic response seen with Evommune’s EVO756, reinforcing confidence in MRGPRX2 inhibition as an effective way to block mast cell activity in skin tissue.

Phipps also underscores that EVO756 is already ahead in development, currently in a Phase IIb trial for chronic spontaneous urticaria with data expected in the near term, positioning Evommune to potentially be first to market among MRGPRX2 inhibitors. Combined with the earlier positive readouts from EVO301 in atopic dermatitis and the lack of clear differentiation of Septerna’s NAM approach versus Evommune’s competitive antagonist, he sees substantial upside potential for the shares if upcoming EVO756 data are favorable, supporting his Buy recommendation.

In another report released on February 19, Morgan Stanley also maintained a Buy rating on the stock with a $54.00 price target.